top of page
Press Releases
December 9, 2021
Mirror Biologics, Inc. Announces Close of a $14 Million Financing Round
November 17, 2021
Mirror Biologics Announces Issuance of US Patent Covering Next Generation Therapeutic Vaccine Technology for Treatment of Cancer and Infectious Disease
September 10, 2021
Mirror Biologics, Inc. Announces Initial Clearance for Phase II/III Clinical Trial (ALIVE) in Advanced Liver Cancer
July 14, 2021
Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase I/II Universal Viral Vaccine Clinical Trial (ALLOPRIME) in Healthy Adults Over 65 Years Old
July 8, 2021
Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase IIB Clinical Trial (STIMVAX) in Patients with Metastatic Colorectal Cancer
Press Archives
July 8, 2020
A ‘Pan-Viral’ Vaccine Designed to Protect the Elderly from Known, and Unknown, Viruses
June 23, 2020
Immunovative Therapies and Mirror Biologics Announce US FDA Clearance of a Universal Anti-Viral Vaccine Phase I/II Clinical Trial for Healthy Elderly Adults
January 29, 2019
Could an Immunotherapy Treatment from Israel Cure Cancer?
December 20, 2018
Immunovative Therapies’ Next-Generation Cancer Vaccine Could Change the Game!
bottom of page